How to Order Novoeight®.

Order by phone.

1-877-NOVO-777

(select option 2)

For product orders, operators are available 24 hours a day, 7 days a week.


For more information on Novoeight®, contact a Novo Nordisk Authorized Trading Partner.

Education for you.

Counsel the Switch brochure


Novo Nordisk offers a comprehensive selection of resources to help educate your patients about hemophilia.
 


Dosing guidelines for Novoeight®.

Novoeight® prefilled syringe


Refer to our dosing tables for recommendations.
 


Have a question? We’re here to help.

Five standing human silhouettes


Talk to a Novo Nordisk Representative about the educational resources available to you.
 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.